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Abstract 
Cholera, caused by bacterium Vibrio cholerae O1, is a severe diarrheal disease with 
an estimated 3-5 million cases and more than 140 000 deaths every year particularly 
affecting children under 5 years of age. 
It can be found all over the world and often causes cholera in places where access to 
clean water or proper sanitary facilities are limited or compromised. Typically cholera 
follows in the wake of natural disasters or man-made catastrophes but it is also 
endemic in many countries including India and Bangladesh. 
Today there are two licensed vaccines available on the market in more than 60 
countries. Despite the fact that these vaccines are effective they are both expensive 
and complicated to manufacture and there is scope and motivation for creating a new 
cheaper and more effective vaccine against cholera. 
First, we have shown that it is possible by genetic manipulation to generate a single 
strain vaccine expressing two phenotypically different phenotypes and shown that the 
candidate vaccine strains elicit similar immune responses as the current licensed 
vaccine Dukoral. This is a huge benefit since it will significantly simplify 
manufacture and reduce production costs. 
Further, we have investigated the naturally occurring Inaba serotype mutants and 
generated a hypothesis as to why O1 serogroup Vibrio cholerae maintains a serotype 
polymorphism. We have conducted a unique study where we could show that 
selective pressure on the circulating strains in the environment is almost certainly 
what is driving serotype transition. 
Taken together, results from this thesis show how the use of bioinformatics can be 
used to target genes and even specific amino acids for mutagenesis in order to modify 
the phenotype of a vaccine strain and understand the unique and fundamental role of 
serotype with respect to epidemic and endemic cholera. 
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